NovoCure Ltd

NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients. The company is headquartered in the United States and serves oncology markets across the U.S., Europe, Japan, and other international markets through direct and partner-based distribution.

−21,2 %

74,5 %

−20,8 %

+8,3 %

2.90

2.71

— NovoCure Ltd
%
TTFields oncology devices85% Portable tumor-treating field systems used to deliver therapy for approved cancer indications.
Consumable arrays and accessories10% Replacement arrays and related consumables used with the therapy devices.
Patient support and service programs5% Training, onboarding, and support services that help patients use the therapy at home.

NovoCure sells primarily to oncology patients through healthcare providers, with therapy adoption driven by physicians...

  • Glioblastoma patientsprimary

    Patients with GBM treated with Optune Gio, typically through neuro-oncology and oncology centers.

  • NSCLC patientsprimary

    Patients with non-small cell lung cancer treated with Optune Lua in approved markets.

  • Pancreatic cancer patientsprimary

    Patients with pancreatic cancer treated with Optune Pax in the U.S. and other approved markets.

  • Hospitals and channel partnerssecondary

    Hospitals and local partners that distribute the product and support patient onboarding in some countries.

NovoCure is a U.S.-based company with revenue generated across the United States and a broad international footprint,...

  • •United States is a core market for approved indications and reimbursement
  • •France and Germany are important European revenue contributors
  • •Other international markets contribute through active patient growth
  • •Greater China is commercialized through a Zai collaboration
  • •Japan uses hospital-based distribution rather than direct-to-patient

NovoCure’s strategy centers on expanding adoption of TTFields in approved indications while pursuing additional...

01
Increase adoption in approved indicationsshort-term

Revenue depends on patient starts and continued use of TTFields therapy.

02
Broaden regulatory approvals and market accessmedium-term

New indications and reimbursement pathways expand the addressable market.

03
Scale global commercialization through partners and trainingmedium-term

The therapy requires physician certification and local market execution.

NovoCure is exposed to regulatory, reimbursement, and commercialization risk because its products require approval,...

high

Concentration in a small number of products

Business prospects depend heavily on a few approved TTFields indications.

Scope
Optune Gio, Optune Lua, Optune Pax
Materiality
high
high

Regulatory and reimbursement delays

Adoption depends on approvals and payer coverage in each market.

Scope
New indications and international expansion
Materiality
high
high

Single-source supply dependence

Loss of a supplier could delay shipments or clinical studies.

Scope
Components and manufactured parts
Materiality
high
medium

Cybersecurity and patient data exposure

The company handles sensitive patient treatment and health information.

Scope
Connected therapy systems and third-party hosting
Materiality
medium
medium

Partner execution risk

Some markets rely on collaborators that control commercialization efforts.

Scope
Greater China and selected distribution markets
Materiality
medium
Revenue recognition
Can affect timing and comparability of reported revenue
Inventory obsolescence
Affects cost of revenues and gross margin
Service pool equipment and operating leases
Affects balance sheet assets and operating expenses
Impairment of long-lived assets
May create non-cash charges
Uncertain tax positions
Can change tax expense and liabilities

electroCore, Inc.

ECOR · Electromedical & Electrotherapeutic Apparatus

NextCure, Inc.

NXTC · Pharmaceutical Preparations

Evommune, Inc.

EVMN · Pharmaceutical Preparations

Nuo Therapeutics, Inc.

AURX · Surgical & Medical Instruments & Apparatus

Intellia Therapeutics, Inc.

NTLA · In Vitro & In Vivo Diagnostic Substances

VYCOR MEDICAL INC

VYCO · Surgical & Medical Instruments & Apparatus

: 29.4.2026